8th January 2019 – Can-Fite BioPharma
Limited issued an announcement, which is summarized as follows:
*Company filed patent application for the utilization of Namodenoson as an anti-obesity drug
*A Phase II study of Namodenoson is enrolling patients for the treatment of NAFLD/NASH
*Data from Phase II study of Namodenoson in advanced liver cancer expected to be released in Q1/19
Can-Fite
BioPharma Limited announced new pre-clinical findings demonstrating that
Namodenoson, inhibits lipid production and fat accumulation in adipocytes
(lipid producing cells). These findings together with the excellent safety profile
of Namodenoson support its potential utilization as an anti-obesity drug.
New
pre-clinical studies of Namodenoson showed a significant decrease in lipid
production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as
lipid producing cells and are also responsible for fat storage. Namodenoson was
also shown to inhibit the proliferation of adipocytes, further hampering the
expansion of fat producing cells. A patent application for the utilization of
Namodenoson as an anti-obesity drug has been filed.
The global
obesity treatment market is lucrative due to the awareness of a link between
chronic diseases and obesity and according to Market Research Future is
expected to reach USD 12 billion by 2023.
The original
website link：